Our esteemed colleagues from Novo Nordisk gave us a boost with their opinion. Yes we are less sophisticated bumpkins with simple business model, but Indianapolis is not Copenhagen on the world stage. However, we also have problems, one being quality of personnel. Often we end up with former CMO employees, with limited qualifications and experience and foreign degrees from less than average institutions.
Big News, Our CEO is leaving. This could be anticipated considering market and stock price decline and incoming revenue reduction from the US market. There have been many causes for this, systemic, business models, personnel structure, manufacturing technologies , operations, to name a few.They could be separately analyzed and this is a task of the company to address these problems. There are also subtle influencing factors, like overly relying on NN Foundation in setting directions and affecting decisions. There was also the ivory tower attitude, as a part strategy. Managerial thinking across company is affected by the same mold coming from Copenhagen Business School. Many managers went to the school, but may lack of daily skills in the fields they operate, like technical or scientific. Often it was enough to have a Danish background and some experience in disciplines not necessarily connected with pharma. Company was lucky with hitting the target with GLP 1, which was relatively simple molecule. This however, could not last considering the above, and other deficiencies. Lilly's less sophisticated approach, is less grandiose, but more business-like. Inviting more NN coworkers to this discussion with a lot to fix.
Having two drugs on the top of the most expensive drugs list is a shame. It is clear that insurance companies increase premiums to all others for select few treated. Time to leave Sarepta.
CEO is driving down the stock by coasting. Preparation for takeover by Roche. Roche waits for further price drop to move. In such case even if Roche offers a premium most of the investors would lose money. Good job Alex
Pharma companies disguise themselves as gentle and caring lambs working hard to save lives. The scale of money involved in rare diseases cure is disproportional to resulting benefits. This is a cover up for industrial elites to live a safe and wealthy existence, whereas their technology lags behind and development progress is much slower than in other industries. Increasingly the work is offshored and the pharma companies mostly add to the cost being the wealth-consuming part in the chain. In contrast to rare diseases and gene and cell therapy that may be focused on small numbers of patients, vaccines are directed towards large populations and must be developed quickly. Being from vaccine field we have little respect for people who doodle for years to develop some marginal drugs and getting rich in the process
I like the operational aspect of my job and my immediate colleagues but I am upset over the unhealthy culture- this is due to hypocritical management wrt core behaviours. Thousands of global redundancies have been made but there are very limited comms internally and none external- so much for transparency.
There is alot of pressure on timelines (ie accelerated) and it feels this is simply to fill management pockets. Staff are treated poorly- on site presence is monitored and put down to 'creating an innovative workspace'. If you don't trust your staff don't employ them. HR has been given the jurisdiction to run the show.
Managers are simply yes men. Annual staff sentiment survey reduced to annual vs 6 monthly. Even then, there is only focus on glory and not the issues. Another core value not met- speak out culture.
This is the pharma industry that is in the dumb and dumber race. There is a third party in this race, the dumbest, and this is the unfortunate patient. This is why pharma business can win the race.
Our provincial inept management cannot exploit deficiencies present at Novo Nordisk.
A mindset problem. Preoccupied with internal struggles and ethnic polarization. This affects bringing any genuine talent to the company. And really no talent is coming, but rather people with certain ties and roots. Experienced and knowledgeable people are ignored. Resembles the dumb and dumber race.
DEI-based hiring hurts company competitiveness. Very odd management force. Keeping appearance of being the progressive regarding technology and business operations leader, but at the same time using many archaic and nonproductive approaches. Making statements of hiring the best, but in reality is filled with mediocre individuals with unsuitable background, like obscure universities, companies from other fields, military and government, cronies or family members of insiders and so on. Experience and competence receive lip service, but in practice do not count much. Redundancy and overlapping activities and responsibilities. Pretending to be like a social club. Some use this for easy coasting. Could reduce employment by 28% and continue operations even better.
There are some who contribute little or are harmful thru their machinations and ignorance, but they still collect high salaries and bonuses and bring their own to build their own internal network, starting already by hiring interns first and later bringing them to the company. Examples could be Brinda B or Ganesh V. Their activities bring multiple damage to the company in both short and long terms.
Too many employees disappear on long parental leave. Hiring substitutes interferes with operation of the company. Solution? Move most of the company to China. Otherwise, Lilly wins.
